AMGEN Inc.

Strong top-line + momentum from “key growth drivers” (good) - Q3 2026 total revenues: $10.4B, +8% YoY. - 6 key growth drivers: +27% YoY, now >70% of product sales. - 17 products delivering double-digit growth; 17 products annualizing at >$1B based on Q3. - Examples: - Repatha: $1.1B, +37% YoY; US new-to-brand prescriptions +>60% YoY. - EVENITY: $751M, +39% YoY; ongoing US demand and Japan leadership. - TEZSPIRE: $538M, +43% YoY, outperforming the severe uncontrolled asthma market. - UPLIZNA (rare disease): $451M, +191% YoY (twice-yearly dosing + payer coverage; expanding internationally). - Biosimilars: $977M, +26% YoY; PAVBLU $300M, +41% YoY.

Late-stage R&D progress across 3 Phase III programs (good, potentially market-changing) - IMDELLTRA (DLL3 TCE) in SCLC - Phase III readouts: DeLLphi-304 showed 40% reduction in risk of death vs chemotherapy in 2L. - DeLLphi-305 (first-line maintenance): median OS 21.1 months vs 12.7 months with IMFINZI alone. - Surprising/important operational improvement: FDA shortened monitoring for first 2 doses in 2L to 6–8 hours (from 22–24 hours); DeLLphi-305 monitoring reported as 1–2 hours, potentially enabling easier rollout in later expansions. - TEZSPIRE (TSLP) in eosinophilic esophagitis - CROSSING (Phase III): met co-primary endpoints at week 24 (histologic remission + swallowing symptoms) and benefits sustained to week 52—framed as first sustained efficacy at 52 weeks for a placebo-controlled EoE biologic. - dazodalibep (CD40L) in Sjogren’s - OASIZ-301 (systemic Sjogren’s, Phase III): statistically significant improvement in ESSDAI (monthly and quarterly dosing) and improvements in dryness-related patient-reported endpoints. - Key “read-through” uncertainty (investor-relevant): company emphasized systemic vs symptomatic are different populations, with symptomatic Phase III data expected later (Q4 / later this year) to confirm transferability.

Financial strength + increased investment (good) - Free cash flow: $3.7B in Q3. - Non-GAAP operating margin: 47%. - R&D spending: +11% YoY. - Capex: $600M in the quarter; supporting manufacturing and potential MariTide launch readiness. - Dividend: $2.52 per share in Q3 (+6% vs Q3 2025), reaffirming shareholder returns.